SERNOVA Forum: Community User: COLOGNE79

@urgestein

€

0,90

2,18 CAD - 200k

2,21 CAD - 111k schon an der T

Info! Endkurs ist der 14.01.2021 nach Börsenschluss Kanada bei Tradegate

Tabelle nach Uhrzeit 1. Leonardo17. 3,40€ - 11:33 2. SchaumerMal94 2,20€ - 11:41 3. Urgestein 3,00€ - 11:46 4. Lumi1989. 5,75€ - 11:47 5. Fth. 6,50€ - 11:48 6.Bionik. 2,10€ - 11:49 7. Commodus. 2,01€ -11:51 8. MrOregon. 4,00€ - 11:56 9. maudi. 2,70€ - 11:58 10. Sernova Fan 2021 40€ - 12:06 11.immerneuling 10,02€ - 12:06 12. Sandrogreen 4.00€ - 12:23 13. Fried1 2,50€ - 12:33 14. tommydeluxe 3,30€ - 12:35 15. kolbaci 2,34€ - 12:36 16. Gina1111 2,42€ - 12:42 17. Herpert 1,65€ - 12:46 18. William T. 1,90€ - 12:53 19. Fried1. 1,60€ - 12:56 20. Tobi87 2,80€ - 13:00 21. Axel361 3,20€ - 13:06 22. ClauSil 1.23€ - 13:23 23. Noname69 1,86€ - 13:40 24. Rooster 2,22€ - 13:41 25. cashflow182 1.87€ - 13:47 26. MtoZ 2,16€ - 14:23 27. mstar1337 3,00€ - 14:31 28. jomanjo 3,15€ - 14:37 29. Betty2021! 1,20€ - 14:38 30. Robo 1976 1,96€ - 14:46 31. cunupii 11,60€ - 15:02

💥🚀💥🚀💥🚀💥🚀💥🚀💥🚀

Irgendwie tendiere ich zu Montag / ab Montag

🤔

Vielleicht wird heute sogar gedrückt tagsüber um Angst zu machen und heute Abend wieder hoch

Kaffee ☕ steht bereit🧐

Mein kribbeln war gestern richtig,anstieg am abend,heute spür ich nichts🤔

So was geht gleich? Oder wieder erst heut abend nach acht die Raketos?

Globe says Sernova a top pick at Leede Jones Gable Sernova Corp (C:SVA) Shares Issued 261,258,258 Last Close 1/6/2022 $2.09 Friday January 7 2022 - In the News The Globe and Mail reports in its Friday, Jan. 7, edition that Leede Jones Gable analyst Doug Loe, who focuses on healthcare and biotechnology, named a Sernova as one of his top picks for the first quarter of the year. The Globe's David Leeder writes in the Eye On Equities column that Mr. Loe rates Sernova "speculative buy," with a $2.50 share target, matching the consensus. Mr. Loe says in a note: "The stock is up 554 per cent since we initiated coverage in early December of 2020 and our price target corresponds to a one-year return of 29.5 per cent. The firm's core technology to which we ascribe market value is still Cell Pouch, a subcutaneously-implantable and vascularizable cell reservoir for preserving function of regenerative cell therapies deployed within it including but not limited to insulin-producing pancreatic islets. The firm has already published impressive preclinical data and for which ongoing clinical testing in a seven-patient Phase I/II hypoglycemia unawareness trial at the University of Chicago has already generated equally-impressive interim safety/efficacy data."